Evidence map›Paper›PMID 33444912›Full record

ArticleCell calcium2021

RyR2 calcium channels in the spotlight-I'm ready for my close up, Dr. Alzheimer!

Grace E Stutzmann

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cell calcium, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Targeting ryanodine receptors to treat human diseases.The Journal of clinical investigation · 2023
    Review
  3. Pathogenesis of sporadic Alzheimer's disease by deficiency of NMDA receptor subunit GluN3A.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Grace E StutzmannRosalind Franklin University of Medicine and Science, Chicago Medical School, Center for Neurodegenerative Disease and Therapeutics, 3333 Green Bay Rd., North Chicago, IL, 60064, United States. Electronic address: Grace.stutzmann@rosalindfranklin.edu.
Rosalind Franklin University of Medicine and Science · US

Funding

Novel Drug Discovery for AD Targeting Ryanodine Calcium ChannelsRF1AG047237 · NIA · ROSALIND FRANKLIN UNIV OF MEDICINE & SCI · PI BUOLAMWINI, JOHN K, STUTZMANN, GRACE E. · 2016 to 2016
$1.9M
Intracellular organelle deficits driving Alzheimer's diseaseRF1AG065628 · NIA · ROSALIND FRANKLIN UNIV OF MEDICINE & SCI · PI SEKLER, ISRAEL, STUTZMANN, GRACE E. · 2020 to 2020
$1.7M
Cellular and synaptic signaling mechanisms driving early AD pathologyR56AG055497 · NIA · ROSALIND FRANKLIN UNIV OF MEDICINE & SCI · PI STUTZMANN, GRACE E. · 2018 to 2018
$390k
NIA NIH HHS R56 AG055497NIA NIH HHS RF1 AG047237
6 · The paper itself

Abstract

While various hypotheses surrounding the etiology of Alzheimer's disease (AD) have waxed and waned over the years, the calcium hypothesis of aging [1] has maintained its steady trajectory since the early 1990's, albeit often as the understudy. Here, Yao et al., [2] further implicate intracellular calcium dysregulation in AD pathogenesis, and focus the spotlight on the elusive ryanodine receptor-2 isoform.

Indexed as

Alzheimer DiseaseRyanodine Receptor Calcium Release ChannelAmyloid beta-PeptidesCalciumHippocampusHumansMemory DisordersAmyloid beta-PeptidesCalciumRyanodine Receptor Calcium Release Channel5xFADA-currentAlzheimer's diseaseAmyloidDendritic spinesHippocampusMemoryRyanodine receptorSynaptic plasticity

Identifiers

PMID33444912
OpenAlexW3118679363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.